126 related articles for article (PubMed ID: 38160916)
21. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
[TBL] [Abstract][Full Text] [Related]
22. Real-Time 3D Image Guidance Using a Standard LINAC: Measured Motion, Accuracy, and Precision of the First Prospective Clinical Trial of Kilovoltage Intrafraction Monitoring-Guided Gating for Prostate Cancer Radiation Therapy.
Keall PJ; Ng JA; Juneja P; O'Brien RT; Huang CY; Colvill E; Caillet V; Simpson E; Poulsen PR; Kneebone A; Eade T; Booth JT
Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1015-21. PubMed ID: 27026307
[TBL] [Abstract][Full Text] [Related]
23. Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy.
Tekatli H; Palacios MA; Schneiders FL; Haasbeek CJA; Slotman BJ; Lagerwaard FJ; Senan S
Radiother Oncol; 2023 Oct; 187():109823. PubMed ID: 37516364
[TBL] [Abstract][Full Text] [Related]
24. The dosimetric error due to uncorrected tumor rotation during real-time adaptive prostate stereotactic body radiation therapy.
Sengupta C; Skouboe S; Ravkilde T; Poulsen PR; Nguyen DT; Greer PB; Moodie T; Hardcastle N; Hayden AJ; Turner S; Siva S; Tai KH; Martin J; Booth JT; O'Brien R; Keall PJ
Med Phys; 2023 Jan; 50(1):20-29. PubMed ID: 36354288
[TBL] [Abstract][Full Text] [Related]
25. Day-to-day reproducibility of prostate intrafraction motion assessed by multiple kV and MV imaging of implanted markers during treatment.
Mutanga TF; de Boer HC; Rajan V; Dirkx ML; Incrocci L; Heijmen BJ
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):400-7. PubMed ID: 22019244
[TBL] [Abstract][Full Text] [Related]
26. Kilovoltage intrafraction monitoring during normofractionated prostate cancer radiotherapy.
Chasseray M; Dissaux G; Lucia F; Boussion N; Goasduff G; Pradier O; Bourbonne V; Schick U
Cancer Radiother; 2020 Apr; 24(2):99-105. PubMed ID: 32201058
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).
Marciscano AE; Wolfe S; Zhou XK; Barbieri CE; Formenti SC; Hu JC; Molina AM; Nanus DM; Nauseef JT; Scherr DS; Sternberg CN; Tagawa ST; Nagar H
BMC Cancer; 2023 Aug; 23(1):781. PubMed ID: 37608258
[TBL] [Abstract][Full Text] [Related]
28. The first clinical implementation of a real-time six degree of freedom target tracking system during radiation therapy based on Kilovoltage Intrafraction Monitoring (KIM).
Nguyen DT; O'Brien R; Kim JH; Huang CY; Wilton L; Greer P; Legge K; Booth JT; Poulsen PR; Martin J; Keall PJ
Radiother Oncol; 2017 Apr; 123(1):37-42. PubMed ID: 28342648
[TBL] [Abstract][Full Text] [Related]
29. Real-time intrafraction prostate motion during linac based stereotactic radiotherapy with rectal displacement.
Legge K; Nguyen D; Ng JA; Wilton L; Richardson M; Booth J; Keall P; O'Connor DJ; Greer P; Martin J
J Appl Clin Med Phys; 2017 Nov; 18(6):130-136. PubMed ID: 28960696
[TBL] [Abstract][Full Text] [Related]
30. Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intrafraction motion during 1.5 T-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer.
Mazzola R; Sicignano G; Cuccia F; Vitale C; Rigo M; Giaj-Levra N; Nicosia L; Figlia V; Ricchetti F; Attinà G; Pastorello E; De Simone A; Gurrera D; Naccarato S; Ruggieri R; Alongi F
Br J Radiol; 2021 Oct; 94(1126):20210521. PubMed ID: 34283646
[TBL] [Abstract][Full Text] [Related]
31. Based on 0.35 T magnetic resonance-guided radiotherapy, what are the nonisotropic PTV margins required for conventional prostate radiotherapy?
Drabble J; Das P; George B; Camilleri P; Morris A
Med Dosim; 2022 Winter; 47(4):334-341. PubMed ID: 35907693
[TBL] [Abstract][Full Text] [Related]
32. MR-guided Gated Stereotactic Radiation Therapy Delivery for Lung, Adrenal, and Pancreatic Tumors: A Geometric Analysis.
van Sörnsen de Koste JR; Palacios MA; Bruynzeel AME; Slotman BJ; Senan S; Lagerwaard FJ
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):858-866. PubMed ID: 30061007
[TBL] [Abstract][Full Text] [Related]
33. Impact of intrafraction prostate motion on clinical target coverage in proton therapy: A simulation study of dosimetric differences in two delivery techniques.
Su Z; Slopsema R; Flampouri S; Li Z
J Appl Clin Med Phys; 2019 Oct; 20(10):67-73. PubMed ID: 31478341
[TBL] [Abstract][Full Text] [Related]
34. Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial.
Ma TM; Ballas LK; Wilhalme H; Sachdeva A; Chong N; Sharma S; Yang T; Basehart V; Reiter RE; Saigal C; Chamie K; Litwin MS; Rettig MB; Nickols NG; Yoon SM; Smith L; Gao Y; Steinberg ML; Cao M; Kishan AU
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):142-152. PubMed ID: 36007724
[TBL] [Abstract][Full Text] [Related]
35. Dosimetric impact of intrafraction motion under abdominal compression during MR-guided SBRT for (Peri-) pancreatic tumors.
Grimbergen G; Eijkelenkamp H; Heerkens HD; Raaymakers BW; Intven MPW; Meijer GJ
Phys Med Biol; 2022 Sep; 67(18):. PubMed ID: 36041431
[No Abstract] [Full Text] [Related]
36. Real-time motion monitoring using orthogonal cine MRI during MR-guided adaptive radiation therapy for abdominal tumors on 1.5T MR-Linac.
Jassar H; Tai A; Chen X; Keiper TD; Paulson E; Lathuilière F; Bériault S; Hébert F; Savard L; Cooper DT; Cloake S; Li XA
Med Phys; 2023 May; 50(5):3103-3116. PubMed ID: 36893292
[TBL] [Abstract][Full Text] [Related]
37. Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia.
Slotman BJ; Clark MA; Özyar E; Kim M; Itami J; Tallet A; Debus J; Pfeffer R; Gentile P; Hama Y; Andratschke N; Riou O; Camilleri P; Belka C; Quivrin M; Kim B; Pedersen A; van Overeem Felter M; Kim YI; Kim JH; Fuss M; Valentini V
Radiat Oncol; 2022 Aug; 17(1):146. PubMed ID: 35996192
[TBL] [Abstract][Full Text] [Related]
38. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
39. Relationship of imaging frequency and planning margin to account for intrafraction prostate motion: analysis based on real-time monitoring data.
Curtis W; Khan M; Magnelli A; Stephans K; Tendulkar R; Xia P
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):700-6. PubMed ID: 22795802
[TBL] [Abstract][Full Text] [Related]
40. Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis.
Pham J; Neilsen BK; Liu H; Cao M; Yang Y; Sheng K; Ma TM; Kishan AU; Ruan D
Med Phys; 2024 Jan; 51(1):612-621. PubMed ID: 38055353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
